Chugai's Xeloda Obtains Additional Indications, Applies Tarceva For Pancreatic Cancer
This article was originally published in PharmAsia News
Executive SummaryThe largest oncology drug maker in Japan, Roche's Japanese unit Chugai Pharmaceutical, obtained approvals for additional indications for anti-cancer drug Xeloda (capecitabine) and additional dosages for Avastin (bevacizumab). The company also submitted an application for an additional indication of pancreatic cancer for Tarceva (erlotinib), currently approved for non-small cell lung cancer in Japan
You may also be interested in...
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).